The interleukin-1 receptor antagonist anakinra improves first-phase insulin secretion and insulinogenic index in subjects with impaired glucose tolerance

Diabetes, Obesity and Metabolism

Volumn 16, Issue 12, 2014, Pages 1269-1273

  van Poppel, P C M ^a   van Asseldonk, E J P ^a   Holst, J J ^b   Vilsboll T ^c   Netea, M G ^a   Tack, C J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

Diabetes mellitus; Drug mechanism; Experimental pharmacology; Type 2 diabetes; cell

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN; INTERLEUKIN 1BETA; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN SENSITIVITY; LETTER; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED; SECRETION (PROCESS); TREATMENT OUTCOME;

BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN-1; TREATMENT OUTCOME;

EID: 84920420168     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12357     Document Type: Letter

References (12)

1. Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc 2003; 78: 447-456.
2. Cnop M, Vidal J, Hull RL et al. Progressive loss of beta-cell function leads to worsening glucose tolerance in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 2007; 30: 677-682.
3. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44: 1249-1258.
4. Donath MY, Storling J, Berchtold LA, Billestrup N, Mandrup-Poulsen T. Cytokines and beta-cell biology: from concept to clinical translation. Endocr Rev 2008; 29: 334-350.
5. Maedler K, Sergeev P, Ris F et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
6. Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356: 1517-1526.
7. Yki-Jarvinen H. Glucose toxicity. Endocr Rev 1992; 13: 415-431.
8. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33(Suppl. 1): S62-S69.
9. Knop FK, Aaboe K, Vilsboll T et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes Metab 2012; 14: 500-510.
10. van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ. Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2011; 96: 2119-2126.
11. Rissanen A, Howard CP, Botha J, Thuren T, for the Global Investigators. Effect of anti-IL-1beta antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial. Diabetes Obes Metab 2012; 14: 1088-1096.
12. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.